Caixin
Caixin Global – Latest China News & Headlines

Home >

ABOUT US

CX Live is Caixin Global's real-time news portal, featuring 24-hour breaking news, short-form analysis, and roundups from business and social media in China.

TRENDING
Chinese Companies Usher in Age of Synthetic Meat
AI Startup Plans IPO at Value of at Least $1 Billion — in China
Huawei’s First 5G Commercial Phone Gets Warm Response Despite Limited Networks
LATEST
Cathay Pacific CEO Hogg Resigns Amid Hong Kong Protests
Ninebot’s New Scooter Can Drive Itself Back to Charging Stations
Oppo to Unveil New Smartphone With 20x Zoom
Chinese Companies Usher in Age of Synthetic Meat
Record-Smashing Chinese Animation to Get Overseas Releases
WTO to Arbitrate China’s Complaints About U.S. Solar-Cell Tariffs
Vipshop Stock Soars After Q2 Results Beat Expectations
Japan Replaces China as Largest Holder of U.S. Government Debt
Huawei’s First 5G Commercial Phone Gets Warm Response Despite Limited Networks
AI Startup Plans IPO at Value of at Least $1 Billion — in China
Alibaba Q2 Revenue Jumps 42%, Beating Estimates But Slower Than Year Earlier
Baidu’s $66 Billion Dive Knocks It Out of China’s Internet Top 5
Beijing Grants Foreign Investors Wider Access to Entertainment Industry
Tencent-Backed Maoyan Turns Profit on Strong Ad Growth
Chinese App-Makers Smell Opportunities in Strict Trash-Sorting Rules
Casino Giant Galaxy Entertainment’s H1 Profit Drops 7% as High-Rollers Stay Away
Chinese Internet Sector Grows 17.9% Year-on-Year: MIIT
Xiaomi Receives Licenses for Second 5G Phone
Coal Industry Looks to Robots for Increased Safety
No Investor Love for Tencent, Lenovo and Luckin in Latest Reports
China Approves Older Novartis MS Drug

By Matthew Walsh / Jul 20, 2019 05:37 AM / Business & Tech

Photo: VCG

Photo: VCG

Novartis International AG won approval in China to sell its multiple sclerosis (MS) drug Gilenya, Reuters reports, deepening the Swiss pharmaceutical giant's business ties to the huge Chinese health care market and promising to shake up the treatment of what has traditionally been a poorly managed disease there.

MS is the most common autoimmune disease affecting the central nervous system. Around 30,000 people in China live with the condition, according to state news agency Xinhua. That compares with nearly 1 million people in the U.S. suffering the disease, according to a study by the National MS Society.

However, low awareness of MS in China means that the actual number of people with the disease may be significantly higher. In May, Chinese doctors urged both health-care professionals and the general public to learn more about the disease, adding that 95% of people knew nothing about MS before they were diagnosed.

MS occurs when the body’s immune system attacks the fatty sheaths around the nerves, disrupting their ability to send messages to one another. As MS progresses, it causes muscle and cognitive problems and can lead to lasting disabilities.

Although there is no one-size-fits-all cure, a number of treatments can significantly slow the progression of MS. China has long been playing catch-up with Western countries in rolling out such treatments, however, and comparatively few are yet available there.

One such drug, teriflunomide — sold under the trademark Aubagio — was approved by the U.S. Food and Drug Administration in 2012 but gained approval in China only last year.

Gilenya sales earned Novartis $825 million during the second quarter, making it the company’s second-largest source of revenue, Reuters said, adding that the drug has been available in the United States for almost a decade but is now being challenged by generic rivals, spurring Novartis’s push into other markets.

Related: In Depth: Why China’s Drug Review Revamp Is Stalling

Contact reporter Matthew Walsh (matthewwalsh@caixin.com)

Share this article
Open WeChat and scan the QR code
Copyright © 2019 Caixin Global Limited. All Rights Reserved.